Thrombocytosis and hepatocellular carcinoma

Dig Dis Sci. 2013 Jun;58(6):1790-6. doi: 10.1007/s10620-012-2527-3. Epub 2013 Jan 12.

Abstract

Background: Thrombocytopenia has been reported to be both a risk factor for hepatocellular carcinoma (HCC) development as well as a prognostic factor. Many HCCs also occur in presence of normal platelets.

Aim: To examine a cohort of HCC patients with associated thrombocytosis.

Methods: Records were examined of a cohort of 634 biopsy-proven and randomly presenting HCC patients without thrombocytopenia.

Results: In the total cohort, 52 patients were identified with thrombocytosis (platelet levels >400 × 10(9)/L) and compared with 582 patients with normal platelet values. The average tumor sizes were 13.1 versus 8.8 cm (p < 0.0001), and their total average bilirubin levels were 0.9 versus 1.5 (p = 0.02), comparing thrombocytosis patients versus normal platelet count HCC patients. These differences were even more pronounced in patients with HCC sizes >5 cm. Thrombocytosis patients were younger and had less cirrhosis, but similar percent with hepatitis B or C or alcohol consumption.

Conclusion: Thrombocytosis in association with HCC occurs in patients with larger tumor sizes and better liver function.

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / complications*
  • Carcinoma, Hepatocellular / pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms / blood
  • Liver Neoplasms / complications*
  • Liver Neoplasms / pathology
  • Logistic Models
  • Male
  • Middle Aged
  • Retrospective Studies
  • Thrombocytosis / complications*
  • Tumor Burden

Substances

  • Biomarkers, Tumor